Cannabinoid receptors as therapeutic targets

Annual Review of Pharmacology and Toxicology

Volumn 46, Issue , 2006, Pages 101-122

  Mackie, Ken ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesia; Endocannabinoid; Fatty acid aminohydrolase; Metabolic syndrome; Neuroinflammation; Obesity

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; AM 1172; AM 1241; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DIAMORPHINE; DRONABINOL; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; HU 308; JWH 133; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NALOXONE; NICOTINE; OL 135; OL 92; RIMONABANT; UCM 707; UNCLASSIFIED DRUG; URB 532; URB 597;

ALCOHOL ABUSE; ANALGESIA; ANIMAL EXPERIMENT; ANXIETY; ARTHRALGIA; BONE GROWTH; DIZZINESS; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNITY; METABOLIC REGULATION; METABOLIC SYNDROME X; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PAIN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SMOKING CESSATION; WITHDRAWAL SYNDROME;

AMIDOHYDROLASES; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CANNABIS; DRUG THERAPY; ENDOCANNABINOIDS; HUMANS; NEURONAL PLASTICITY; RECEPTORS, CANNABINOID; TETRAHYDROCANNABINOL;

ANIMALIA; CANNABIS;

EID: 33144480327     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.46.120604.141254     Document Type: Review

References (152)

1. Black SC. 2004. Cannabinoid receptor antagonists and obesity. Curr. Opin. Investig. Drugs 5:389-94
2. Di Carlo G, Izzo AA. 2003. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin. Investig. Drugs 12:39-49
3. Di Marzo V, Bifulco M, De Petrocellis L. 2004. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3:771-84
4. Drysdale AJ, Platt B. 2003. Cannabinoids: mechanisms and therapeutic applications in the CNS. Curr. Med. Chem. 10:2719-32
5. Jarvinen T, Pate DW, Laine K. 2002. Cannabinoids in the treatment of glaucoma. Pharmacol. Ther. 95:203-20
6. Kirkham TC, Williams CM. 2004. Endocannabinoid receptor antagonists: potential for obesity treatment. Treat. Endocrinol. 3:345-60
7. Mendizabal VE, Adler-Graschinsky E. 2003. Cannabinoid system as a potential target for drug development in the treatment of cardiovascular disease. Curr. Vasc. Pharmacol. 1:301-13
8. Russo EB. 2004. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro. Endocrinol. Lett. 25:31-39
9. Walter L, Stella N. 2004. Cannabinoids and neuroinflammation. Br. J. Pharmacol. 141:775-85
10. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-64
11. Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR. 1992. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 263:1118-26
12. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. 1988. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 247:1046-51
13. Melvin LS, Milne GM, Johnson MR, Subramaniam B, Wilken GH, Hewlett AC. 1993. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 44:1008-15
14. Hewlett AC, Barth F, Bonner TI, Cabral G, Casellas P, et al. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54:161-202
15. Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65
16. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, et al. 1993. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214:173-80
17. Mackie K, Lai Y, Westenbroek R, Mitchell R. 1995. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15:6552-61
18. Twitchell W, Brown S, Mackie K. 1997. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78:43-50
19. Derkinderen P, Toutant M, Burgaya F, Le Bert M, Siciliano JC, et al. 1996. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science 273:1719-22
20. Gomez Del Pulgar T, De Ceballos ML, Guzman M, Velasco G. 2002. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 277:36527-33
21. Sanchez C, Galve-Roperh I, Rueda D, Guzman M. 1998. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol. 54:834-43
22. Waksman Y, Olson JM, Carlisle SJ, Cabral GA. 1999. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther. 288:1357-66
23. Di Marzo V, Griffin G, De Petrocellis L, Brandi I, Bisogno T, et al. 2002. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther. 300:984-91
24. Hajos N, Freund TF. 2002. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43:503-10
25. Randall MD, Kendall DA, O'Sullivan S. 2004. The complexities of the cardiovascular actions of cannabinoids. Br. J. Pharmacol. 142:20-26
26. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, et al. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-49
27. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. 1993. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA 90:7656-60
28. Calignano A, La Rana G, Piomelli D. 2001. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol. 419:191-98
29. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, et al. 2003. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425:90-93
30. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:83-90
31. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, et al. 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:89-97
32. Stella N, Schweitzer P, Piomelli D. 1997. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773-78
33. Bradshaw HB, Walker JM. 2005. The expanding field of cannabimimetic and related lipid mediators. Br. J. Pharmacol. 144:459-65
34. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, et al. 1994. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-91
35. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. 2004. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279:5298-305
36. Cadas H, di Tomaso E, Piomelli D. 1997. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17:1226-42
37. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. 1996. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16:3934-42
38. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, et al. 2003. Cloning of the first sn1-DAG upases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163:463-68
39. Piomelli D. 2003. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4:873-84
40. Breivogel CS, Childers SR. 2000. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J. Pharmacol. Exp. Ther. 295:328-36
41. Breivogel CS, Selley DE, Childers SR. 1998. Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem. 273:16865-73
42. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. 2000. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 57:1045-50
43. Luk T, Jin W, Zvonok A, Lu D, Lin XZ, et al. 2004. Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br. J. Pharmacol. 142:495-500
44. Mackie K, Devane WA, Hille B. 1993. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:498-503
45. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, et al. 2001. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry 58:322-28
46. Huestis MA, Preston KL, Heishman SJ, Boyd ST, Mondick J, et al. 2004. Antagonism of inhalded cannabis by single and multiple doses of SR141716 (rimonabant) in male subjects with a history of cannabis use. 2004 Symp. Cannabinoids, p. 86, Paestum, Italy
47. McFarland MJ, Barker EL. 2004. Anandamide transport. Pharmacol. Ther. 104:117-35
48. Cravatt BF, Lichtman AH. 2003. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol. 7:469-75
49. McKinney MK, Cravatt BF. 2005. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74:411-32
50. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, et al. 2002. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 99:10819-24
51. Dinh TP, Kathuria S, Piomelli D. 2004. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol. Pharmacol. 66:1260-64
52. Ghafouri N, Tiger G, Razdan RK, Mahadevan A, Pertwee RG, et al. 2004. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br. J. Pharmacol. 143:774-84
53. Freund TF, Katona I, Piomelli D. 2003. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83:1017-66
54. Alger BE. 2002. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. 68:247-86
55. Gerdeman GL, Lovinger DM. 2003. Emerging roles for endocannabinoids in long-term synaptic plasticity. Br. J. Pharmacol. 140:781-89
56. Kim J, Isokawa M, Ledent C, Alger BE. 2002. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J. Neurosci. 22:10182-91
57. Kreitzer AC, Regehr WG. 2001. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717-27
58. Varma N, Carlson GC, Ledent C, Alger BE. 2001. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 21: RC188
59. Wilson RI, Kunos G, Nicoll RA. 2001. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 31:453-62
60. Wilson RI, Nicoll RA. 2001. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588-92
61. Carlson G, Wang Y, Alger BE. 2002. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat. Neurosci. 5:723-24
62. Kreitzer AC, Carter AG, Regehr WG. 2002. Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum. Neuron 34:787-96
63. Chevaleyre V, Castillo PE. 2003. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38:461-72
64. Gerdeman GL, Ronesi J, Lovinger DM. 2002. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 5:446-51
65. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Ranimes G, et al. 2002. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-34
66. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. 2002. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc. Natl. Acad. Sci. USA 99:8384-88
67. Fourgeaud L, Mato S, Bouchet D, Hemar A, Worley PF, Manzoni OJ. 2004. A single in vivo exposure to cocaine abolishes endocannabinoid-mediated long-term depression in the nucleus accumbens. J. Neurosci. 24:6939-45
68. Mato S, Chevaleyre V, Robbe D, Pazos A, Castillo PE, Manzoni OJ. 2004. A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity. Nat. Neurosci. 7:585-86
69. Chevaleyre V, Castillo PE. 2004. Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron 43:871-81
70. Wagner JA, Varga K, Kunos G. 1998. Cardiovascular actions of cannabinoids and their generation during shock. J. Mol. Med. 76:824-36
71. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, et al. 2001. Endocannabinoids acting at vascular CB1receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med. 7:827-32
72. Bloom AS, Tershner S, Fuller SA, Stein EA. 1997. Cannabinoid-induced alterations in regional cerebral blood flow in the rat. Pharmacol. Biochem. Behav. 57:625-31
73. Stein EA, Fuller SA, Edgemond WS, Campbell WB. 1998. Selective effects of the endogenous cannabinoid arachidonylethanolamide (anandamide) on regional cerebral blood flow in the rat. Neuropsychopharmacology 19:481-91
74. Kunos G, Batkai S, Offertaler L, Mo F, Liu J, et al. 2002. The quest for a vascular endothelial cannabinoid receptor. Chem. Phys. Lipids 121:45-56
75. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, et al. 2004. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110:1996-2002
76. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. 2005. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-97
77. Iversen L. 2003. Cannabis and the brain. Brain 126:1252-70
78. Smith PF. 2004. GW-1000. GW Pharmaceuticals. Curr. Opin. Investig. Drugs 5:748-54
79. Berman JS, Symonds C, Birch R. 2004. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112:299-306
80. Wade DT, Makela P, Robson P, House H, Bateman C. 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10:434-41
81. Foltin RW, Fischman MW, Byrne MF. 1988. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11:1-14
82. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, et al. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:240-44
83. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, et al. 1997. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272:22330-39
84. Pan X, Ikeda SR, Lewis DL. 1998. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol. 54:1064-72
85. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, et al. 1998. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 284:291-97
86. 1 antagonists. IDrugs 8:53-66
87. Williams CM, Rogers PJ, Kirkham TC. 1998. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol. Behav. 65:343-46
88. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, et al. 2003. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:R345-53
89. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, et al. 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-25
90. Verty AN, McGregor IS, Mallet PE. 2004. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci. Lett. 354:217-20
91. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. 1998. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63:PL113-17
92. Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, et al. 2005. Endocannabinoid action at hepatic CB1 receptors regulates fatty acid synthesis: role in diet-induced obesity. J. Clin. Invest. 115:1298-305
93. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, et al. 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112:423-31
94. Boyd ST, Fremming BA. 2005. Rimonabant-a selective CB1 antagonist. Ann. Pharmacother. 39:684-90
95. Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, et al. 2004. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail. 6:501-8
96. Fattore L, Cossu G, Spano MS, Deiana S, Fadda P, et al. 2004. Cannabinoids and reward: interactions with the opioid system. Crit. Rev. Neurobiol. 16:147-58
97. Le Foll B, Goldberg SR. 2005. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. 312:875-83
98. Lupica CR, Riegel AC, Hoffman AF. 2004. Marijuana and cannabinoid regulation of brain reward circuits. Br. J. Pharmacol. 143:227-34
99. Corchero J, Manzanares J, Fuentes JA. 2004. Cannabinoid/opioid crosstalk in the central nervous system. Crit. Rev. Neurobiol. 16:159-72
100. Chaperon F, Soubrie P, Puech AJ, Thiebot MH. 1998. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 135:324-32
101. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, et al. 2001. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav. Brain Res. 118:61-65
102. De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN. 2003. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 168:164-69
103. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. 2003. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide(SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J. Pharmacol. Exp. Ther. 306:93-102
104. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL. 1990. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156-62
105. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. 2002. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J. Neurosci. 22:1146-54
106. Wachtel SR, de Wit H. 2000. Naltrexone does not block the subjective effects of oral delta(9)-tetrahydrocannabinol in humans. Drug Alcohol Depend. 59:251-60
107. Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O. 2002. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43:857-67
108. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. 2002. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Pharmacol. 13:451-63
109. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R. 2002. Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine. Br. J. Pharmacol. 135:564-78
110. Tanda G, Pontieri FE, DiChiara G. 1997. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mul opioid receptor mechanism. Science 276:2048-50
111. Gallate JE, Mallet PE, McGregor IS. 2004. Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats. Psychopharmacology 173:210-16
112. Gallate JE, Saharov T, Mallet PE, McGregor IS. 1999. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur. J. Pharmacol. 370:233-40
113. Mechoulam R, Parker L. 2003. Cannabis and alcohol-a close friendship. Trends Pharmacol. Sci. 24:266-68
114. Basavarajappa BS, Hungund BL. 2002. Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. Prostaglandins Leukot. Essent. Fatty Acids 66:287-99
115. Walker JM, Huang SM. 2002. Cannabinoid analgesia. Pharmacol. Ther. 95:127-35
116. Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A. 2004. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J. Pharmacol. Exp. Ther. 308:446-53
117. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, et al. 2003. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. USA 100:10529-33
118. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, et al. 2005. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. USA 102:3093-98
119. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, et al. 2001. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93:239-45
120. Nackley AG, Makriyannis A, Hohmann AG. 2003. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119:747-57
121. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG. 2004. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J. Neurophysiol. 92:3562-74
122. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, et al. 2003. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99:955-60
123. Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V. 2004. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur. J. Neurosci. 20:2311-20
124. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. 2003. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci. 17:2750-54
125. Bab I. 2005. The skeleton: stone bones or stoned heads? In Cannabinoids as Therapeutics, ed. R. Mechoulam, pp. 201-6. Basel, Switzerland: Birkhauser Verlag AG
126. Idris AI, van't Hof RJ, Greig IR, Ridge SA, Baker D, et al. 2005. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. 11:774-79
127. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, et al. 2005. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434:782-86
128. Coffey RG, Snella E, Johnson K, Pross S. 1996. Inhibition of macrophage nitric oxide production by tetrahydrocannabinol in vivo and in vitro. Int. J. Immunopharmacol. 18:749-52
129. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB. 1989. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23:73-81
130. Srivastava MD, Srivastava BI, Brouhard B. 1998. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40:179-85
131. Zurier RB. 2003. Prospects for cannabinoids as anti-inflammatory agents. J. Cell Biochem. 88:462-66
132. 130a. Benito C, Nunez, E, Tolon, RM, Carrier EJ, Rabano A, et al. 2003. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23:11136-41
133. 130b. Benito C, Kim WK, Chavarria I, Hillard CJ, Mackie K, et al. 2005. A glial endogenous cannabinoid system is upregulated in the brains of macques with simian immunodeficiency virus-induced encephalitis. J. Neurosci. 25:2530-36
134. Bouaboula M, Dussossoy D, Casellas P. 1999. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J. Biol. Chem. 274:20397-405
135. Brown SM, Wager-Miller J, Mackie K. 2002. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim. Biophys. Acta 1576:255-64
136. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF. 2002. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther. 302:73-79
137. Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, et al. 2005. Discovery of a potent, selective, and efficacious class of reversible alpha- ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J. Med. Chem. 48:1849-56
138. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, et al. 2004. Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J. Med. Chem. 47:4998-5008
139. Tarzia G, Duranti A, Tontini A, Piersanti G, Mor M, et al. 2003. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J. Med. Chem. 46:2352-60
140. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. 1999. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA 96:12198-203
141. Richardson JD, Aanonsen L, Hargreaves KM. 1997. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:R3-4
142. Lichtman AH, Shelton CC, Advani T, Cravatt BF. 2004. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109:319-27
143. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, et al. 2003. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9:76-81
144. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, et al. 2004. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311:441-48
145. Beltramo M, Piomelli D. 2000. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 11:1231-35
146. Hillard CJ, Jarrahian A. 2003. Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol. 140:802-8
147. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG. 2003. Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. USA 100:4269-74
148. de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Viso A, Lopez-Rodriguez ML, Ramos JA. 2002. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur. J. Pharmacol. 449:99-103
149. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, et al. 2004. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl. Acad. Sci. USA 101:8756-61
150. Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Fowler CJ, Tiger G, et al. 2003. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J. Med. Chem. 46:1512-22
151. Ortega-Gutierrez S, Hawkins EG, Viso A, Lopez-Rodriguez ML, Cravatt BF. 2004. Comparison of anandamide transport in FAAH wild-type and knock-out neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry 43:8184-90
152. Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Fowler CJ, Tiger G, et al. 2003. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. Eur. J. Med. Chem. 38:403-12